ABSTRACT
Although social exclusion violates the basic needs of sense of control, self-esteem, meaningful existence, and belongingness, it is unknown if fear of missing out (FoMO) or attachment anxiety contributes to one's sense of ostracism and each of these basic needs. We aimed to identify if baseline scores in attachment anxiety and/or FoMO predict how excluded an individual feels after playing an online ball-tossing game designed to include or exclude them and if these constructs tap into basic needs that ostracism has shown to threaten. A sample of 193 young adults participated in this online study. After completing measures of demographics, FoMO, and attachment anxiety, each participant played Cyberball, a virtual ball-tossing game. Under the guise of playing with two other human participants, this paradigm consists of pre-programmed conditions of either inclusion, which entails receiving 10 of the total 30 ball tosses, or exclusion, which consists of receiving the ball only twice at the beginning of the game. Participants then completed post-measures of state ostracism, basic needs, and attention checks and were debriefed regarding the nature of the Cyberball game. We found that FoMO, but not attachment anxiety, predicted how ostracized one felt. Likewise, FoMO was inversely related to control, belongingness, and meaningful existence. Attachment anxiety did not predict any of the basic needs examined in the study. We conclude FoMO may be less about the experience one misses out on and more about the fear of being excluded. Future research is needed to evaluate if people experience increases in state FoMO while excluded and if baseline mood influences our findings.
ABSTRACT
The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.
